金因康® (Diquafosol Sodium Eye Drops), has received marketing approval from the China National Medical Products Administration (NMPA) [Approval Number: 國藥准字 H20254149].
2025-05-22
View details
Record-Breaking Revenue of HK$553.0M and Net Profit of HK$82.8M，First-ever Dividend was HK$0.277 Cents Per Share，Strengthening Presence in Osteoporosis，Ophthalmology, and Aesthetic Medical Markets
2025-03-27
View details
2nd December 2024 –Uni-Bio Science Group Limited is pleased to announce two significant milestones that demonstrate the Group’s continued growth and innovation in the field of medical aesthetics and dermatological solutions.
2024-12-02
View details
Achieved Record High Revenue of HK$273.6M and Net Profit of HK$67.4M Further Penetration to Osteoporosis, Ophthalmology, and Medical Aesthetic Device Markets
2024-08-28
View details
Recently, Uni-Bio Science Group Limited is pleased to announce a strategic cooperation with Chongqing Minji Medical Device Co., Ltd.
2024-07-10
View details
京公网安备 11011402013046号京ICP备17029593号-2
